



# SUVEN Life Sciences

**Communication to investors**  
**June 2013**

13-Aug-13

*2013-14 Q1 results*



# Risk statement

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this presentation may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause these statements to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive; Suven may not undertake to update any forward-looking statements that may be made from time to time.

# FINANCIAL QUICK VIEW

## Quarter 1 – June 2013



- Growth in revenue 57.38%
- Growth in PAT 273.86%
- Growth in EBIDTA 233.20%
- Growth in Pre-R&D EBIDTA 139.41%
- R&D cost on revenue 7.10%

# MAJOR PROFITABILITY RATIOS




	Q1 June 13	Q1 June 12
PAT to Income	26.62%	11.21%
EBIDTA to Income	41.30%	19.51%
Cash Flow to Income	28.50%	13.79%
Pre-R&D EBITDA to Income	48.40%	31.82%

13-Aug-13

2013-14 Q1 results



# INCOME COMPARISON




13-Aug-13

2013-14 Q1 results



# PROFIT COMPARISON




13-Aug-13

2013-14 Q1 results



# EBIDTA COMPARISON




13-Aug-13

2013-14 Q1 results



# R & D – EXPENDITURE




13-Aug-13

2013-14 Q1 results



# PRE-R&D EBIDTA




13-Aug-13

2013-14 Q1 results



# PRE-R&D CASHFLOW



13-Aug-13

2013-14 Q1 results



# Updates for the quarter

- During the quarter there were major qualitative achievements with the grant of 16 (sixteen) product patents to Suven's drug discovery pipeline which consists of 13 molecules out of which twelve (12) molecules currently in pre-clinical stage of development in addition to developmental candidate SUVN-502 for Alzheimer's disease and Schizophrenia.
- Suven has a patent profile of 18 inventions, 569 product patents and 36 process patents.